The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pulmonary veno-occlusive disease
Publications
Certain MC, Chaumais MC, Jaïs X, Savale L, Seferian A, Parent F, Georges M, Favrolt N, Bourdin A, Boissin C, Cottin V, Traclet J, Renard S, Noel V, Picard F, Girerd B, Ghigna MR, Perros F, Sitbon O, Bonniaud P, Humbert M, Montani D
Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C.
Chest 2021 03;159;1197-1207 — 2021 03 — 1197-1207
Lung transplantation for mitomycin-induced pulmonary veno-occlusive disease.
Presse medicale (Paris, France : 1983) 2017 Dec;46;1223-1225 — 2017 Dec — 1223-1225
Perros F, Günther S, Ranchoux B, Godinas L, Antigny F, Chaumais MC, Dorfmüller P, Hautefort A, Raymond N, Savale L, Jaïs X, Girerd B, Cottin V, Sitbon O, Simonneau G, Humbert M, Montani D
Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models.
Circulation 2015 Sep 01;132;834-47 — 2015 Sep 01 — 834-47
Pulmonary veno-occlusive disease after neoadjuvant mitomycin chemotherapy and surgery for lung carcinoma.
Lung cancer (Amsterdam, Netherlands) 2002 May;36;213-5 — 2002 May — 213-5
Pulmonary veno-occlusive disease after chemotherapy.
Human pathology 1983 Jan;14;88-91 — 1983 Jan — 88-91